Navigation Links
US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting
Date:5/26/2011

UPFRONT study.Trials in Progress:Joanne Blum, MD, Texas OncologyPoster #37D

Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive-(ER+) breast cancer.Allen Cohn, MD, Rocky Mountain Cancer CentersLinda DeMarco, MD, FACP, New York Oncology HematologyJean Stephenson, RN, Texas OncologyBrian Ulrich, MD, Texas OncologyPeter Yu, MD, Camino Medical GroupPoster #45F

    Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 vs gemcitabine alone in previously untreated patients with advanced pancreatic cancer.Frankie Ann Holmes, MD, Texas OncologyPoster #40G

    Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • A phase 3 trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC).Thomas E. Hutson, DO, PharmD, FACP, Texas OncologyPoster #47H

    Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors.Publish Only:Joyce O'Shaughnessy, MD, Texas Oncology


  • Eribulin mesylate EMBRACE study: Survival analysis excluding patients rechallenged with therapies of the same class.Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology


  • Phase III study of axitinib versus sorafenib for treatment of patients with metastatic renal cell carcinoma.  TRIAL in PROGRESS.William Berry, MD, Cancer Centers of North CarolinaMark Fleming, MD, Virginia Oncology AssociatesMichael Kolodziej, MD, New York Oncology HematologySanjiv Awasthi, Texas OncologyThomas E. Hutson, DO, PharmD, FACP, Texas OncologyDanko Martincic, MD, Cancer Care No
    '/>"/>


  • SOURCE US Oncology, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
    3. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
    4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
    5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
    6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
    7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
    8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
    9. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
    10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
    11. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... Feb. 27, 2015 The role of the ... but one thing hasn,t changed: face-to-face meetings are seen ... with Key Opinion Leaders. Yet at the ... valuable type of interaction, field medical teams within the ... interactions. This is just one of the challenges addressed ...
    (Date:2/27/2015)... YORK , Feb. 27, 2015  Pomerantz LLP ... Pharmaceuticals, Inc. ("Vitae" or the "Company") (NASDAQ: ... Robert S. Willoughby at rswilloughby@pomlaw.com or ... Vitae and certain of its officers and/or directors have ... Act of 1934.  On February 27, ...
    (Date:2/27/2015)...  Acsis Inc., the market leader for supply chain ... John DiPalo , Acsis, Chief Strategy Officer, has ... Executive 2015 Provider Pro to Know. The award ... help prepare their companies, and customers, supply chains for ... list of Provider Pros to Know is featured in ...
    Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
    ... immunogenicity results for seasonal vaccine program follows positive results from ... plans to initiate a study of the seasonal vaccine in ... ROCKVILLE, Md., Dec. 11 Novavax, Inc. (Nasdaq: ... Phase IIa human clinical trial of its seasonal influenza VLP ...
    ... 11 ,Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ... ) and Alkermes, Inc. (Nasdaq: ALKS ... Administration (FDA) recently indicated that the ongoing extension ... the basis for demonstrating,comparability between intermediate-scale clinical trial ...
    Cached Medicine Technology:Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 2Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 3Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 4Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 5Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 6Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 2Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 3Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 4Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 5Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 6Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 7
    (Date:2/28/2015)... 2015 Pioneer Millworks reclaimed USA wood ... & Construction Materials Show, an annual, premier sustainable building ... suppliers and top manufacturers of the latest building products, ... sourced and manufactured by Pioneer Millworks from their ... Japan at restaurants, hotels, retailers, and corporate offices. ...
    (Date:2/28/2015)... (PRWEB) February 28, 2015 Kaylie Corrigan, ... alcohol treatment center , and current student obtaining her ... has implemented a weekly forum in psychoeducation on substance ... in Flagstaff, AZ as part of her studies. , ... need for support and counseling at the high school ...
    (Date:2/28/2015)... February 28, 2015 Developers of FCPX ... a new overlay plugin for Final Cut Pro X entitled ... “FCPX Overlay Chromatic gives users total control over 6k lens ... CEO of Pixel Film Studios. “FCPX Overlay Chromatic was professionally ... to use interface.” , FCPX Overlay Chromatic Grunge 6K is ...
    (Date:2/28/2015)... (PRWEB) February 28, 2015 The World ... and learning materials to potential EMTs and firefighters, recently ... Bitcoins as a way to raise charitable donations for ... in Medellin, Columbia, will be held on March 29, ... run will begin at 3:30 p.m. , To ...
    (Date:2/27/2015)... (PRWEB) February 27, 2015 OnChip ... (IPD), has introduced miniature, wire bondable, silicon ESD (Electrostatic ... LED markets. The ESD88NP and ... away from sensitive LED and IC products. These ... Varistors (MLV). All devices meet the requirements of ...
    Breaking Medicine News(10 mins):Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3
    ... York have achieved a breakthrough of sorts in cancer ... to a key position on cancer cells and gives ... of advanced colorectal cancer patients. ,IMC-C225, the new ... to interfere with the epidermal growth factor receptor, a ...
    ... is one of the worst types of chronic pain. ... painful condition. But now there’s good news for the ... the most popular forms of alternative medicine, is supposed ... ,A team led by Dr. Jeanette Ezzo, Washington, ...
    ... of the journal Epidemiology, high levels of DDT found in ... function. The human body metabolises DDT to DDE. An international ... 16 to 28 who had not been exposed to DDT ... levels correlated to low levels of testosterone, low semen volume ...
    ... Millions of postmenopausal women suffer from sexual dysfunctions- ... physiological and psychological problems. ,However if the ... these problems can be treated properly. Almost all ... develop changes in genital organs-particularly a condition known ...
    ... in four countries have unanimously opined that the deadly ... from an oral polio vaccine used in Africa in ... no scientific evidence to back them up. ,The ... Germany, should help free the polio vaccine manufactured by ...
    ... Thursday that plans are afoot to consider listing on US ... bourses after 2002," Pratap C Reddy, chairman of the Apollo ... business plan for the post-2002 period. ,Though further details ... plans to raise the number of beds to 8000 from ...
    Cached Medicine News:
    ... all those involved with healthcare decisions to ... latest evidence in their field of interest ... year as the volume of evidence increases. ... the best single source available for continually ...
    ... CVMstat® provides leading ... of topics involving all ... including sections on diagnosis ... arterial and venous disease. ...
    ... to the management of common ... a response from leading experts ... more common, and often poorly ... It is a "how-to" guide ...
    The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan...
    Medicine Products: